Institut Paoli-calmettes

This study tests whether removing the kidney after successful immunotherapy can help patients with metastatic kidney cancer stop all treatment and stay cancer-free. About 60 adults whose tumors have shrunk significantly with immunotherapy will either have surgery and stop therapy…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have strong chemotherapy will take DASATINIB for up to 3 months. Doctors will che…

This study tests whether adults with acute myeloid leukemia (AML) who are doing well on a two-drug chemotherapy combination (venetoclax and azacitidine) can safely stop or reduce their treatment. About 50 participants will stop the drugs and be closely monitored for relapse. Thei…

This study is collecting blood and tumor samples from 200 people with non-small cell lung cancer to find biological markers that predict whether immunotherapy will work. Researchers will compare samples taken before treatment and at the time the disease gets worse. The goal is to…